RESUMEN
Changes in the gut microbiome have pivotal roles in the pathogenesis of acute graft-versus-host disease (aGVHD) after allogenic haematopoietic cell transplantation (allo-HCT)1-6. However, effective methods for safely resolving gut dysbiosis have not yet been established. An expansion of the pathogen Enterococcus faecalis in the intestine, associated with dysbiosis, has been shown to be a risk factor for aGVHD7-10. Here we analyse the intestinal microbiome of patients with allo-HCT, and find that E. faecalis escapes elimination and proliferates in the intestine by forming biofilms, rather than by acquiring drug-resistance genes. We isolated cytolysin-positive highly pathogenic E. faecalis from faecal samples and identified an anti-E. faecalis enzyme derived from E. faecalis-specific bacteriophages by analysing bacterial whole-genome sequencing data. The antibacterial enzyme had lytic activity against the biofilm of E. faecalis in vitro and in vivo. Furthermore, in aGVHD-induced gnotobiotic mice that were colonized with E. faecalis or with patient faecal samples characterized by the domination of Enterococcus, levels of intestinal cytolysin-positive E. faecalis were decreased and survival was significantly increased in the group that was treated with the E. faecalis-specific enzyme, compared with controls. Thus, administration of a phage-derived antibacterial enzyme that is specific to biofilm-forming pathogenic E. faecalis-which is difficult to eliminate with existing antibiotics-might provide an approach to protect against aGVHD.
Asunto(s)
Bacteriófagos , Enterococcus faecalis , Microbioma Gastrointestinal , Enfermedad Injerto contra Huésped , Adulto , Anciano , Animales , Femenino , Humanos , Masculino , Ratones , Persona de Mediana Edad , Adulto Joven , Bacteriófagos/enzimología , Bacteriófagos/genética , Biopelículas/efectos de los fármacos , Biopelículas/crecimiento & desarrollo , Disbiosis/complicaciones , Disbiosis/microbiología , Enterococcus faecalis/efectos de los fármacos , Enterococcus faecalis/genética , Enterococcus faecalis/crecimiento & desarrollo , Enterococcus faecalis/metabolismo , Enterococcus faecalis/virología , Heces/microbiología , Vida Libre de Gérmenes , Enfermedad Injerto contra Huésped/complicaciones , Enfermedad Injerto contra Huésped/microbiología , Enfermedad Injerto contra Huésped/prevención & control , Enfermedad Injerto contra Huésped/terapia , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Técnicas In Vitro , Intestinos/efectos de los fármacos , Intestinos/microbiología , Perforina/metabolismo , Factores de Riesgo , Trasplante Homólogo/efectos adversos , Secuenciación Completa del Genoma , Farmacorresistencia Bacteriana/efectos de los fármacos , Antibacterianos/farmacologíaRESUMEN
BACKGROUND: Although vaccination is recommended for protection against invasive pneumococcal disease, the frequency of pneumococcal pneumonia is still high worldwide. In fact, no vaccines are effective for all pneumococcal serotypes. Fusion pneumococcal surface protein A (PspA) has been shown to induce a broad range of cross-reactivity with clinical isolates and afford cross-protection against pneumococcal challenge in mice. Furthermore, we developed prime-boost-type mucosal vaccines that induce both antigen-specific IgG in serum and antigen-specific IgA in targeted mucosal organs in previous studies. We investigated whether our prime-boost-type immunization with a fusion PspA was effective against pneumococcal infection in mice and cynomolgus macaques. METHODS: C57BL/6 mice were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan. Six weeks later, PspA was administered intranasally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some mice were given intranasal Streptococcus pneumoniae and the severity of infection was analyzed. Macaques were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan at week 0 and week 4. Then, 13 or 41 weeks later, PspA was administered intratracheally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some macaques were intranasally administered S. pneumoniae and analyzed for the severity of pneumonia. RESULTS: Serum samples from mice and macaques injected with antigens in combination with CpG oligodeoxynucleotides and/or curdlan contained antigen-specific IgG. Bronchial samples contained antigen-specific IgA after the fusion PspA boosting. This immunization regimen effectively prevented S. pneumoniae infection. CONCLUSIONS: Prime-boost-type immunization with a fusion PspA prevented S. pneumoniae infection in mice and macaques.
RESUMEN
The Richter-scale 9.0 earthquake that struck Northeast Japan on March 11th, 2011 caused a tsunami that damaged the Fukushima No. 1 Power Plant and released enormous amounts of radiation into the environment. Many area residents were evacuated to several protected fallout shelters. Prior to the tsunami, Fukashima had around 505,760 residents over 65 years of age, comprising 24.9% of the city's pre-tsunami population of Fukushima (City of Fukushima, 2011). The high proportion of elderly contributed to difficulties encountered in evacuating and caring for Fukushima citizens in the immediate aftermath of the disaster. The first author participated in disaster relief efforts in two fallout shelters in Fukushima. This article was written to share her post-disaster care experience and learned knowledge with medical care professionals in Taiwan and other high earthquake risk areas. The article also offers guidelines on appropriate medical personnel response and behavior with regard to disaster response. We hope this experience-sharing offers positive suggestions for the future and facilitates improved disaster-care education in East Asia and enhanced international cooperation on disaster rescue.